Frontlight ResearchEarly access
Active, not recruitingNo phase
Cephea South America Feasibility Study
Key facts
- Who runs it
- Abbott Medical Devices
- Where
- Brazil and Chile3 sites in 2 countriesChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 20 people, planned
- Started
- 17 Jun 2025
- Expected to end
- Sept 2028
- Type of study
- Interventional
- Treatments tested
- Cephea Mitral Valve System
- Record updated
- 11 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Mitral valve disease resulting in mitral regurgitation (MR ≥ Grade III) and/or severe mitral valve stenosis (mitral valve area ≤ 1.5cm²) per American Society of Echocardiography criteria
- LVEF ≥ 30%
- In the judgement of the Site Heart Team, transcatheter therapy is deemed more appropriate than open heart surgery
Who cannot take part
- Prior surgical or interventional treatment that interferes with the Cephea valve delivery or function
- Need for emergent or urgent surgery
Where is this trial?
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
The objective of this study is to evaluate the preliminary safety and effectiveness of the Cephea Mitral Valve System for the treatment of symptomatic patients with mitral valve disease (including mitral regurgitation, mitral stenosis and mixed mitral valve disease) in whom transcatheter therapy is deemed more appropriate than open heart surgery.
The group in the trial
- Cephea TMVRTreatment being tested
Treatment of symptomatic patients with mitral valve disease (including mitral regurgitation, mitral stenosis and mixed mitral valve disease) with the Cephea Mitral Valve System
Treatment: Cephea Mitral Valve System
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Record updated
- 11 September 2026